Tazobactam

Addressing the widespread challenge of β-lactam antibiotic resistance in the clinical treatment of multidrug-resistant bacterial infections, tazobactam, as a classic β-lactamase inhibitor, irreversibly binds to class A and class C β-lactamases produced by bacteria, thereby protecting the antibacterial activity of compatible antibiotics such as piperacillin and cefoperazone from being destroyed. It is usually formulated into compound preparations with penicillins and cephalosporins, and is clinically mainly used for the treatment of moderate to severe pneumonia, abdominal infections, urinary tract infections, sepsis and other conditions caused by sensitive bacteria. The applicable population covers adults and pediatric patients who meet the medication indications, and it is a core adjuvant component in the combination medication regimen for severe infections.

The global tazobactam market size was approximately USD 1.28 billion in 2023, and the compound annual growth rate from 2024 to 2030 is expected to remain around 4.2%. The core growth driver comes from the expanding demand for compound preparations driven by the rising resistance rate of Gram-negative bacteria worldwide. China is the core supplier of tazobactam API in the world, with its production capacity accounting for more than 85% of the global total production capacity. A mature generic supply system has been formed in the domestic market. After the implementation of centralized procurement, the clinical utilization rate of compound preparations has further increased, directly driving the sustained and steady growth of demand for upstream APIs.

The original research enterprise of tazobactam is Taiho Pharmaceutical Co., Ltd. of Japan, and the original brand name is "Tazocin" (a compound preparation combined with piperacillin). The core compound patent of tazobactam expired around 2003 in major global markets. The main dosage form of the original marketed product is compound preparation for injection, with specifications of piperacillin 2g/tazobactam 0.25g and piperacillin 4g/tazobactam 0.5g. This compound preparation has been included in the Chinese *Catalogue of Reference Preparations for Chemical Drugs* and the FDA Reference Preparation Catalogue. As of the retrieval time point, more than 30 domestic enterprises have completed the registration (status A) of tazobactam API in CDE, and more than 60 compound preparation varieties such as piperacillin-tazobactam and cefoperazone-tazobactam have been approved for marketing. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for tazobactam API. Most products are in stock, and orders for in-stock products placed before 16:00 will be shipped on the same day. Meanwhile, the products meet the compliance requirements of multiple regulations including the Chinese Pharmacopoeia and FDA, and can fully meet the needs of API manufacturers in quality research, stability study and registration declaration.